When cutaneous SCC metastasizes, it does so in a predictable manner, usually involving only the regional lymph nodes. 3, 4, 7, 9, 10 Once clinically detectable nodal metastasis has occurred, the prognosis is poor, with reported 5-year survival rates of approximately 26%. 2, 6, 7, [11] [12] [13] The dilemma therefore lies in the management of high-risk cutaneous SCCs with no clinical or radiologic evidence of metastatic disease or a clinical N0 status. There has been much debate in the literature over this matter, and currently, no clear-cut guidelines exist. 1, 12, 14 Different authors advocate watchful waiting, additional radiation therapy (XRT), regional elective lymph node dissection (LND), or a combination of LND and XRT. 1, 2, 9, 12, 14, 15 Also of concern are high-risk tumors of the lateral forehead, temple, ear, or upper lip with potential drainage to the parotid gland. Controversy exists in the management of these tumors because of the significant morbidity associated with surgical or radiation treatment of the parotid versus the poor prognosis and high morbidity of subsequent tumor involvement. Often a multidisciplinary team approach can be useful in managing individual cases. 2, 9, 16, 17 Selective lymphadenectomy or sentinel lymph node (SLN) biopsy has been used in the staging and treatment of malignant melanoma, breast cancer, Merkel cell carcinoma, oral and genital SCC, and other solid tumors. 5, 18 The concept of the sentinel node is based on the orderly progression of metastasis within the cutaneous lymphatics. The advantages of this procedure are the ability to identify the primary draining lymph nodes and nodal basins, accurately predict the histologic status of the draining nodal basins, offer prognostic information, guide additional therapy, and avoid unnecessary morbidity. SLN biopsy has not yet been proven to influence survival. 18, 19 The application of SLN biopsy in SCC has been mostly limited to oral, oropharyngeal, and genital SCCs. 20, 21 Its role in the management of these tumors is promising. A recent study of 40 cases of oral and oropharyngeal SCCs with clinically negative cervical nodes demonstrated that one half contained microscopic metastases on SLN biopsy. 18 Similarly, de Hulla et al. 21 found positive nodes in 34% of 59 patients with SCC of the vulva using SLN biopsy. Although mucosal SCCs typically have a higher metastatic rate than cutaneous SCCs, SLN biopsy for cutaneous SCC has been shown to be feasible, even in conjunction with Mohs micrographic surgery. 5, 22 There are, however, no reported series examining the use of SLN biopsy in cutaneous SCC.
The aim of this study is to report our institutional experience with sentinel lymphadenectomy in the management of high-risk cutaneous SCC. From 1995 to 2001, nine patients with high-risk cutaneous SCCs and clinically negative regional nodes consented to undergo preoperative lymphoscintigraphy and sentinel lymphadenectomy at the time of tumor excision. We herein report our results, including short-term clinical follow-up.
Methods
Since 1995, a total of nine patients from the Cutaneous Oncology Program at the H. Lee Moffitt Cancer Center received preoperative lymphoscintigraphy and SLN biopsy for high-risk cutaneous SCC. Each of these cases was identified as high risk for metastasis by meeting at least one of nine reported criteria. 4 All patients had no clinical evidence of nodal metastases or a N0 status. The diagnosis of SCC was confirmed on histologic examination. Six of the cases met two criteria for high risk, whereas three cases met one criterion. Seven cases were larger than 2 cm in diameter. Three met histologic criteria of poor differentiation or depth of invasion. Two were recurrent, and three were on high-risk sites (lip and helix). One patient was human immunodeficiency virus positive; however, this has not been definitively shown to correlate with more aggressive SCCs. 4, [23] [24] [25] Patient data and tumor characteristics are presented in Table 1 .
All patients underwent preoperative lymphoscintigraphy to identify the approximate number and location of SLNs. Filtered (0.2-micron filter) technetium-labeled sulfur colloid was injected intradermally in a four-quadrant pattern around the primary tumor or the previous biopsy site. Dynamic and delayed images were obtained to show the lymphatic drainage pattern of the primary tumor, as well as the anatomic relationships of potential SLNs. An intradermal tattoo was used to mark the location of potential SLNs.
Patients were taken to the operating room for complete excision of primary tumor, intraoperative lymphatic mapping, and SLN biopsy under general anesthesia. Excision and sentinel node biopsy were performed by the plastic surgery department. Mohs micrographic surgery is not available at this institution. A combination lymphatic mapping technique was used that included a vital blue dye and radiocolloid to identify the SLN during surgery. The SLN harvest was performed 2 to 24 hours after lymphoscintigraphy when the radioactivity in SLNs was still detectable. Thus, reinjection of radiocolloid was avoided. Vital blue dye was injected around the primary tumor or previous biopsy site at the beginning of the surgical procedure. Ten minutes after the injection, a small incision was made at the site of the intradermal tattoo. Lymph nodes with a blue-stained afferent lymphatic or tinged a blue color were excised and submitted as SLNs. Using a hand-held g probe, ''hot'' lymph nodes with sufficient ratios of radioactivity versus background (more than 3:1 in vivo) or versus a neighboring non-SLN (more than 10:1 ex vivo) were also harvested as SLNs. Additional non-SLNs were removed for histologic examination in one case (patient 5). An intraoperative frozen section of a SLN was performed in one case (patient 2).
SLNs were sectioned at 2-to 3-mm intervals and completely submitted for pathologic examination. Specimens obtained were then stained conventionally with hematoxylin and eosin. Immunohistochemical staining with anticytokeratin cocktail (AE1/AE3) was performed on several histologically negative nodes to evaluate for micrometastatic disease.
Results
Conventional histologic examination of primary tumor wide local excisions confirmed complete excision in all cases. SLNs were identified and excised in all patients ( Table 2 ). Locations matched anatomic Histologically positive nodes were found in four of nine (44%) cases. Nodal metastases were identified with hematoxylin and eosin staining in all four cases. Although immunostaining of SLN for detection of micrometastatic disease is considered by many to be the ''standard of care'' in melanoma and breast carcinoma, it is not performed on a routine basis for the detection of micrometastatic SCC. This is because the tumor cells are characteristically quite large and/or present in large clusters. In our small series, in the one case in which cytokeratin immunostaining was used (patient 5), no additional metastases were noted.
In the four patients with positive SLNs, the degree of involvement ranged from 10% to 100% of the nodal area. Extracapsular extension was present in two cases. Three of the four patients with positive SLNs underwent therapeutic LND. One of the three patients demonstrated additional metastatic disease in the affected nodal basin; the remaining two had no additional disease identified. One patient did not receive LND but underwent postoperative XRT to the primary site and draining nodal basin. In this small series, the number of nonsentinel nodes excised after a positive sentinel node biopsy was lower than expected for a classic completion dissection. In this pilot study, we were attempting to investigate the feasibility of the techniques of mapping and sentinel node biopsy but avoid the morbidity of complete node dissection. When this procedure becomes validated, it will be reasonable to offer a truly ''complete'' node dissection to these patients.
Two of the four patients with positive SLNs died of metastatic disease within 2 years. Patient 1 had a 4.5cm recurrent, moderately differentiated SCC of the wrist and one positive SLN from the axilla; therapeutic LND revealed four negative nodes. This patient developed local recurrence in the bone at 5 months, requiring an above-the-elbow amputation, followed by recurrence in the stump. This patient eventually died of systemic metastatic disease with no clinical evidence of local or regional recurrence at the time of death. Patient 2 had an 11-cm poorly differentiated SCC of the lower leg and received an intraoperative therapeutic left groin dissection after frozen section revealed one positive groin SLN. Two of five nodes from this LND revealed metastatic disease. This patient is known to have died of systemic metastases within 4 months, with no clinical evidence of local or regional recurrence. All five patients with negative SLNs are alive and without disease at a median follow-up of 8 months (mean of 13 months). Preoperative lymphoscintigraphy and SLN biopsy were well tolerated by all patients.
Discussion
Selective lymphadenectomy has the potential to play an important role in the management of high-risk cutaneous SCCs in patients with a clinical N0 status, and this is the first reported case series that examines the usefulness of this technique in this setting. Although this case series is small, with limited follow-up and no controls, the data illustrate several important points regarding the possibility of enhanced management of this malignancy.
Similar to its use in melanoma and breast cancer, SLN biopsy may contribute to the staging of high-risk cutaneous SCCs. Staging is based on evidence of regional or distant metastasis. 2, 14 Detection of regional nodal spread, which accounts for 85% of metastases, depends on either clinical detection of lymphadenopathy or radiologic studies. Detecting distant metastases is based on a thorough history and physical as well as appropriate radiologic or laboratory testing. 1, 14 There is no standard method for detecting subclinical metastases. Elective LND can be performed to evaluate for subclinical nodal metastatic disease; however, is not advocated because of the high morbidity-to-benefit ratio. 2, 14, 18 The use of preoperative lymphoscintigraphy and SLN biopsy may help to identify patients with subclinical metastases and thus theoretically at higher risk for overt metastatic disease. This study identified four of nine (44%) patients with subclinical nodal disease. This rate of subclinical regional metastasis is consistent with numbers found in genital and oropharyngeal SCCs, as well as within range of reported metastatic rates for similar high-risk cutaneous SCCs. 4, 18, 21 Patients with positive SLNs were upstaged and treated with additional therapy for micrometastatic disease in all four cases. The five patients with negative SLN histology were spared further therapy.
Sentinel node status may also provide prognostic information. High-risk cutaneous SCCs adequately excised before metastasis have an excellent cure rate. Conversely, metastatic disease, be it regional or distant, carries a grim prognosis with 5-year survival rates of 26% despite therapy. 2, 7, 14 Metastases are discovered within the first 2 years of diagnosis in 80% of the cases and are usually indicated by palpable regional lymph nodes. 14 Therefore, a large proportion of the tumors that will eventuate in metastatic disease likely has subclinical regional nodal disease before lesion excision. Two of four patients with positive SLNs in this study developed clinical metastases and died of their disease within 2 years, although neither appeared to have developed clinical regional disease. The other two patients are alive without disease (with limited follow-up). This mortality rate of 50% is consistent with reported rates for metastatic SCC. All patients with negative SLNs are alive without disease.
Preoperative lymphoscintigraphy as well as SLN status can help guide additional therapy. Postoperative XRT or LND has not been proven to increase survival rates in high-risk cutaneous SCC with clinically N0 status and is not routinely performed. If any benefit is to be gained from further therapy, however, it is more likely for those with subclinical disease of the nodes. In our study, all four patients with positive SLNs received some form of additional therapy, whereas the remaining five patients with negative SLNs received no further treatment. Furthermore, therapy such as XRT or LND may be more accurately focused on the proper draining nodal basins, as drainage patterns identified by lymphoscintigraphy are discordant from classic anatomic teaching in 63% of head and neck lesions and 32% of truncal lesions. 26 In this series, additional therapy consisted of either therapeutic LND or XRT of the identified draining nodal basins.
The use of preoperative lymphoscintigraphy and sentinel lymphadenectomy may ultimately improve survival rates in patients with high-risk cutaneous SCC. Identifying subclinical regional metastases, as well as locating the correct draining nodal basin, would guide more directed additional therapy at an earlier and theoretically more curable stage of disease progression. There is perhaps more potential for control of metastatic disease in SCC than in melanoma given SCCs propensity to metastasize predominantly to regional lymph nodes and its radiosensitivity. In our study, two of four patients who received adjuvant therapy for positive SLNs are alive without disease, although the follow-up time is very limited.
Another surgical consideration is the method used for excision of the primary tumor. Mohs surgery is felt by some to be the treatment of choice for high-risk SCC, with lower recurrence rates than standard excision. 1, 2, 5 One of the nine patients in this series did demonstrate local recurrence. Although Mohs micrographic surgery was not performed in this series, the combination of Mohs micrographic surgery and sentinel lymphadenectomy has been shown to be feasible in one case report; however, there were logistical difficulties. 5 By optimizing local tumor clearance as well as evaluating the sentinel node status, this combination may eventually improve management of high-risk SCCs.
Another advantage of preoperative lymphoscintigraphy and SLN biopsy is its minimal associated morbidity. In general, this procedure spares the morbidity associated with more extensive LND, including lymphedema and nerve damage, but these adverse events have been reported. 27 An additional risk is allergic or anaphylactic reactions to the injectable dye. 28, 29 The procedures were well-tolerated by all patients in this study with no complications or excess recovery time. SLN biopsy also spares the associated morbidity of potentially unnecessary additional therapy in those with negative nodes. Patients in our study with negative SLNs did not receive further therapy.
The identification of SCCs as high risk in this study was based on the most commonly reported characteristics; however, multivariate-proven prognostic factors for recurrence and metastasis are still lacking. In this study, no definitive statements can be made regarding clinical or histologic characteristics of primary tumor and incidence of positive SLNs. Similarly, no predictions can be made regarding the extent of positive SLN involvement and prognosis.
In summary, sentinel lymphadenectomy is a lowmorbidity procedure that may prove to have an important role in the management of patients with high-risk cutaneous SCC and a clinical N0 status. This study, although small and with limited follow-up, suggests that the incidence of subclinical metastasis is high. The ability to reliably detect subclinical metastases may contribute to staging and also may improve survival by guiding additional therapy and removing small foci of disease. The evaluation and management of high-risk cutaneous SCC still await identification of multivariate-proven prognostic factors for recurrence and metastasis. Larger studies are also needed to define further the role of SLN biopsy in the management of these high-risk malignancies.
